Compare iShares MSCI Malaysia ETF (EWM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Viatris Inc — how do they compare? iShares MSCI Malaysia ETF trades at $26.65 (market cap $256.41M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 78.1× iShares MSCI Malaysia ETF's market cap, and Viatris Inc pays a 2.75% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Viatris Inc for 57 Days on average.
| EWM | VTRS | |
|---|---|---|
Market Cap | $256.41M | $20.03B |
Volume | 111,962 | 14,109,977 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $18.27 |
52-Week Low | $25.33 | $9.74 |
Typical Hold Time | 66 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM is trading at $26.61, down 1.88% today, with a bearish technical signal from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment. The stock lacks recent news coverage, creating uncertainty around current business developments and financial performance.
The outlook for EWM is cautious due to insufficient fundamental data and bearish technical indicators. Investment opportunities hinge on future earnings clarity, while risks include potential weak financials and negative market sentiment. Investors need updated SEC filings or analyst reports to gauge true valuation and growth prospects.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
